BioAge Labs (BIOA) Common Equity (2023 - 2026)

BioAge Labs has disclosed Common Equity across 4 years of filings, most recently posting $374.9 million for Q2 2026.

• In Q2 2026, Common Equity rose 27.18% year-over-year to $374.9 million; the TTM figure through Jun 2026 stood at $374.9 million (up 27.18% YoY), while the FY2025 annual figure was $272.1 million, down 15.81% from the prior year.
• Common Equity came in at $374.9 million for Q2 2026 at BioAge Labs, down from $379.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $379.1 million in Q1 2026 to a low of -$197.1 million in Q2 2024.
• Average Common Equity over 4 years is $153.3 million, with a median of $286.1 million recorded in 2025.
• Year-over-year, Common Equity surged 304.88% in 2024 and decreased 15.81% in 2025.
• Over 4 years, Common Equity stood at -$173.4 million in 2023, then soared by 286.35% to $323.1 million in 2024, then decreased by 15.81% to $272.1 million in 2025, then surged by 37.81% to $374.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $374.9 million in Q2 2026, $379.1 million in Q1 2026, and $272.1 million in Q4 2025.